X4 Pharmaceuticals, Inc
For the period ended Sep 30, 2025. Filed Nov 5, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2025 · Filed Nov 5, 2025
XFOR$3.25-2.6%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements Stockholders’ Equity (unaudited)
CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY
(In thousands, except share amounts)
| Common Stock · AdditionalPaid-InCapital · Accumulated Other ComprehensiveLoss · AccumulatedDeficit · TotalStockholders’Equity | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Shares · Amount | ||||||||||
| Balance at December 31, 2024 | 5,698,231 | $6 | $537,620 | $(122) | $(515,355) | $22,149 | ||||
| Vesting of restricted stock units | 90,514 | — | — | — | ||||||
| Stock-based compensation expense | 519 | 519 | ||||||||
| Unrealized loss on marketable securities | (6) | (6) | ||||||||
| Net income | 282 | 282 | ||||||||
| Balance at March 31, 2025 | 5,788,745 | $6 | $538,139 | $(128) | $(515,073) | $22,944 | ||||
| Proceeds from the sale of common stock, less discounts | 2,140,729 | 2 | 5,982 | 5,984 | ||||||
| Issuance of common stock under employee stock purchase plan | 18,473 | — | 46 | 46 | ||||||
| Vesting of restricted stock units | 12,000 | — | — | — | ||||||
| Stock-based compensation expense | 748 | 748 | ||||||||
| Unrealized loss on marketable securities | (10) | (10) | ||||||||
| Net loss | (25,741) | (25,741) | ||||||||
| Balance at June 30, 2025 | 7,959,947 | $8 | $544,915 | $(138) | $(540,814) | $3,971 | ||||
| Sale of common stock, net of issuance costs | 14,504,156 | 15 | 86,666 | 86,681 | ||||||
| Vesting of restricted stock units | 112,692 | — | — | — | ||||||
| Exercise of pre-funded warrants | 2,569,616 | 2 | — | 2 | ||||||
| Stock-based compensation expense | 760 | 760 | ||||||||
| Unrealized gains on marketable securities | 20 | 20 | ||||||||
| Net loss | (29,815) | (29,815) | ||||||||
| Balance at September 30, 2025 | 25,146,411 | $25 | $632,341 | $(118) | $(570,629) | $61,619 | ||||
CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY
(In thousands, except share amounts)
| Common Stock · AdditionalPaid-InCapital · Accumulated Other ComprehensiveLoss · AccumulatedDeficit · TotalStockholders’ Equity | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Shares · Amount | |||||||||||
| Balance at December 31, 2023 | 5,581,153 | $6 | $529,117 | $(119) | $(477,905) | $51,099 | |||||
| Vesting of restricted stock units | 16,773 | — | — | — | |||||||
| Stock-based compensation expense | 1,739 | 1,739 | |||||||||
| Unrealized loss on marketable securities | (36) | (36) | |||||||||
| Net loss | (51,766) | (51,766) | |||||||||
| Balance at March 31, 2024 | 5,597,926 | $6 | $530,856 | $(155) | $(529,671) | $1,036 | |||||
| Issuance of common stock under employee stock purchase plan | 7,835 | — | 158 | 158 | |||||||
| Vesting of restricted stock units | 777 | — | — | — | |||||||
| Stock-based compensation | 2,428 | 2,428 | |||||||||
| Unrealized loss on marketable securities | (4) | (4) | |||||||||
| Net loss | 90,833 | 90,833 | |||||||||
| Balance at June 30, 2024 | 5,606,538 | $6 | $533,442 | $(159) | $(438,838) | $94,451 | |||||
| Vesting of restricted stock units | 10,504 | 1 | 1 | ||||||||
| Stock-based compensation expense | 1,820 | 1,820 | |||||||||
| Unrealized gains on marketable securities | 45 | 45 | |||||||||
| Net loss | (36,696) | (36,696) | |||||||||
| Balance at September 30, 2024 | 5,617,042 | $6 | $535,263 | $(114) | $(475,534) | $59,621 | |||||
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.